ICU Medical Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名45/206位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價181.40。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
ICU Medical Inc評分
相關信息
行業排名
45 / 206
全市場排名
132 / 4560
所屬行業
醫療設備與耗材
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
6
分析師
買入
評級
181.400
目標均價
+26.17%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
ICU Medical Inc亮點
亮點風險
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
公司代碼ICUI
公司ICU Medical Inc
CEOJain (Vivek)
網址https://www.icumed.com/
常見問題
ICU Medical Inc(ICUI)的當前股價是多少?
ICU Medical Inc(ICUI)的當前股價是 142.670。
ICU Medical Inc 的股票代碼是什麼?
ICU Medical Inc的股票代碼是ICUI。
ICU Medical Inc股票的52週最高點是多少?
ICU Medical Inc股票的52週最高點是175.510。
ICU Medical Inc股票的52週最低點是多少?
ICU Medical Inc股票的52週最低點是107.000。
ICU Medical Inc的市值是多少?
ICU Medical Inc的市值是3.52B。
ICU Medical Inc的淨利潤是多少?
ICU Medical Inc的淨利潤為-117.69M。
現在ICU Medical Inc(ICUI)的股票是買入、持有還是賣出?
根據分析師評級,ICU Medical Inc(ICUI)的總體評級為買入,目標價格為181.400。